Can genes and drug levels predict transplant success?
NCT ID NCT03555851
First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This study is looking at how a person's genes and the amount of the drug cyclophosphamide in their body affect the risk of graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will study 120 transplant recipients and their donors. The goal is to find ways to better prevent GVHD while keeping the transplant's cancer-fighting effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide
- What this could lead to
- If successful, this could help doctors personalize cyclophosphamide dosing to better prevent graft-versus-host disease while preserving the anti-cancer effect.
- What could go wrong
- This is an early-stage observational study, not a treatment trial. It may not lead to changes in practice, and results may not apply to all transplant types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.